Vladimir Kovčin

Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial

Nasser H. Hanna, R. Kaiser, Richard N. Sullivan et al. · Lung Cancer · 2016 · 86 citations

Medicine, Pharmacology, Clinical Trials +8

Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non–Small-Cell Lung Cancer (GALAXY-2)

Rathi N. Pillai, Dean A. Fennell, Vladimir Kovčin et al. · Journal of Clinical Oncology · 2019 · 70 citations

Randomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma

S. Jelić, Vladimir Kovčin, N Milanović et al. · European Journal of Cancer · 1997 · 47 citations

Medicine, Metronomic Therapy, Pathology +5

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Joseph Gligorov, Beyhan Ataseven, Mark Verrill et al. · European Journal of Cancer · 2017 · 46 citations

Breast Oncology, Medicine, Primary Analysis +7

Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study

S. Jelić, Labuda Mitrović, Davorin Radosavljević et al. · Lung Cancer · 2001 · 43 citations

Mitomycin C, Medicine, Pathology +9